Soligenix Inc.
USUSDSoligenix Inc. (LSE:0A6I) — Biotechnology: Pharmaceutical Preparations. Biržų, kuriose prekiaujama bendrovės akcijomis, skaičius: 2. Šiame puslapyje — kaina ir grafikas, dividendai, didžiausi akcininkai ir akcijų skaičiaus istorija.
Apie Įmonę
- Svetainė
- soligenix.com
- Sektorius
- Health Care · Biotechnology: Pharmaceutical Preparations
- Būstinė
- PRINCETON, United States
- Generalinis Direktorius
- Christopher J. Schaber
- Darbuotojai
- 13
- Biržoje Nuo
- 04.03.2021 (LSE:0A6I)
- Apyvartoje Esančios Akcijos
- Laisvai Apyvartinės Akcijos
- 21.66 mln.
- Rinkos Kapitalizacija
- 7.91 mln. USD
- Insaideriai
- 4.59%
- Instituciniai Investuotojai
- 6.72%
- Šaka (SIC)
- Pharmaceutical Preparations
- P/E
- nuostolis
- FCF
- −10.3 mln. USD
- Skola
- 0 USD
- Pelnas ir FCF – už 12 mėnesių iki 30.06.2026 (naujausia įmonės ataskaita).
- NAV
Aprašymas
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX945, an IDR technology that is in Phase 2a study to treat aphthous ulcers in Behçet's disease; and SGX302, an IDR technology, which is in Phase 2a study for the treatment of mild-to-moderate psoriasis. Its Public Health Solutions segment engages in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a, 1b, and 1c clinical trials; SGX943, a therapeutic candidate in preclinical studies for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; CiVax, a vaccine candidate for the prevention of COVID-19; and vaccine programs that target filoviruses, such as Marburg and Ebola. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in September 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
Didžiausi Akcininkai
| Turėtojas | Dalis | Akcijos | Ataskaitos Data |
|---|---|---|---|
| Citadel Advisors Llc | 0.96% | 209 507 | 2026-06-30 |
| Jane Street Group, LLC | 0.95% | 207 492 | 2026-06-30 |
| Xtx Topco Ltd | 0.72% | 157 119 | 2026-06-30 |
| Geode Capital Management… | 0.55% | 120 267 | 2026-06-30 |
| Vanguard Capital Managem… | 0.37% | 81 005 | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 0.37% | 81 005 | 2026-06-30 |
| Fidelity Concord Street… | 0.35% | 76 176 | 2026-07-31 |
| Virtu Financial LLC | 0.28% | 60 903 | 2026-06-30 |
| Vanguard Fiduciary Trust… | 0.25% | 53 914 | 2026-06-30 |
| Northern Trust Corporati… | 0.17% | 38 046 | 2026-06-30 |
| SCHABER CHRISTOPHER J (C… | ≈0.07% | 15 511 | 2025-10-02 |
| Fidelity Concord Street… | 0.07% | 14 459 | 2026-07-31 |
| Fidelity Concord Street… | 0.04% | 8 054 | 2026-07-31 |
| Morgan Stanley | 0.02% | 3 592 | 2026-06-30 |
| Jones Financial Companie… | 0.01% | 1 236 | 2026-06-30 |
Prisijunkite su Google